GlassScriptPhysician profile
Erin M Sarzynski
NPI 1669676680
$1,509.80
in general payments reported to CMS, 2019-2025
22 companies · $875 in 2025
The $875 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $635 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $270.84 | 2024-2025 | |
| Abbvie INC. | $220.18 | 2024-2025 | |
| Novo Nordisk INC | $200.23 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.49 | 2024-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $96.84 | 2024-2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $68.50 | 2025 | Rexulti |
| Lilly USA, LLC | $68.24 | 2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $58.54 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.92 | 2024-2025 | Caplyta |
| Abbott Laboratories | $49.43 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $33.82 | 2025 | |
| Amgen INC. | $33.32 | 2025 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $28.08 | 2025 | Auvelity |
| Averitas Pharma INC. | $23.88 | 2024 | Qutenza |
| Alnylam Pharmaceuticals INC. | $22.45 | 2025 | Givlaari |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $18.43 | 2024 | Skyclarys |
| Phadia US INC. | $15.43 | 2025 | Immunocap |
| Exact Sciences Corporation | $15.28 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $15.27 | 2025 | Bexsero, Shingrix |
| Currax Pharmaceuticals LLC | $14.51 | 2025 | Contrave |
| Coloplast Corp | $14.32 | 2024 | |
| Phathom Pharmaceuticals, INC. | $13.80 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Sarzynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.